Key statistics
On Tuesday, Cullinan Therapeutics Inc (CGEM:NSQ) closed at 12.19, -9.23% below its 52-week high of 13.43, set on Feb 03, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 12.08 |
|---|---|
| High | 12.55 |
| Low | 11.83 |
| Bid | 11.76 |
| Offer | 13.64 |
| Previous close | 11.83 |
| Average volume | 665.55k |
|---|---|
| Shares outstanding | 59.08m |
| Free float | 58.70m |
| P/E (TTM) | -- |
| Market cap | 720.14m USD |
| EPS (TTM) | -3.68 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 21:00 GMT.
More ▼
- Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
- Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones
- Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting
- Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
- Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
- Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
- Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
- Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
- Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
- Cullinan Therapeutics to Participate in Upcoming Investor Conferences
More ▼
